Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced that Martina Widman, M.Sc. in Mechanical Engineering from the Royal Institute of Technology in Stockholm and employed in Diamyd Medical since 2008, as of September 1 succeeds Erika Hillborg as Director of Clinical Development. “I warmly thank Erika for her ten years in the company,” says Ulf Hannelius, President and CEO of Diamyd Medical. “Erika built the clinical operations at Diamyd Medical and under her leadership, several clinical studies skillfully and cost effectively were conducted in the US and in Europe. Her efforts have been extremely important in Diamyd Medical's development.” “It feels sad to leave Diamyd Medical,” says Erika Hillborg. “These years have been amazing and intensely fun and stimulating. Now is the right time for me to hand over and move on to new projects.” Erika Hillborg is succeeded by Martina Widman, M.Sc. in Mechanical Engineering from the Royal Institute of Technology in Stockholm with a specialization in Biomedical Engineering. Martina Widman will be a member of Diamyd Medical's management team. About Diamyd Medical Diamyd Medical is dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in stem cell and medical technology. Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based Therapy (ABT) based on the exclusively licensed GAD-molecule. The Company’s licensed technologies for GABA and Gliadin have also potential to become key pieces of the puzzle of a future solution to prevent, treat or cure autoimmune diabetes, and also certain inflammatory diseases. At this time six clinical studies are ongoing with Diamyd®. Diamyd Medical is one of the major shareholders in the stem cell company Cellaviva AB. Stem cells can be expected to be used in Personalized Regenerative Medicine (PRM), for example for restoration of beta cell mass in diabetes patients where the autoimmune component of the disease has been arrested. Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA. Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser. For further information, please contact: Ulf Hannelius, President and CEO Phone: +46 736 35 42 41. E-mail: ulf.hannelius@diamyd.com Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com. This information is information that Diamyd Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on September 1, 2016.
Diamyd Medical appoints new head of Clinical Development
Top 10 Most Recent News Articles
College Towns Spark Entrepreneurial Booms Across US
Entrepreneurial Sparks Fly in Unlikely Places Turns out, it's not just the Silicon Valleys of the world creating startups—sometimes it's the coffee-driven college town where innovation quietly roots itself. GoDaddy's inaugural list of America's Most Entrepreneurial College Towns decimates the old idea that only big cities can be entrepreneurial havens. Instead, eight...
Continue Reading
ChinaMarket: Linyi's Gateway for Global Buying Delegations
Unlocking Trade Potential in Linyi, China Linyi, in Shandong province, has flipped the switch on the sourcing circuit with one powerful invite to global buying delegations. As we sit perched on the fence of an economically tangled world, China's open arms to Southeast and Central Asian buyers mark a significant shift towards more fluid trade connections. The Fourth Linyi...
Continue Reading
Tradier Brokerage Data Breach Sparks Legal Probe
Data Breach Drama Hits Tradier Brokerage Picture a broker-dealer like Tradier Brokerage, out in Charlotte, getting its customers' details hanging out there for the world to see. A calamity, courtesy of a cyberattack on their third-party vendor, Etna Software Corp. And we're talking Social Security numbers, tax IDs—emails across Texas and Massachusetts were popping up...
Continue Reading
The Sift: Slickdeals’ Game-Changing Black Friday Tool
Revolutionizing Black Friday Planning Off we go, diving headfirst into the chaotic whirlpool that is Black Friday shopping. Slickdeals seems to think they’ve got the golden ticket with The Sift, and I can't say they're wrong. Instead of the traditional paper ad scans we've been sifting through since the dawn of time, The Sift brings all announced deals into one...
Continue Reading
MacGregor Revamps Fleet for Wallenius Wilhelmsen Deal
MacGregor's Big Move: Retrofitting 35 Vessels I'll tell you something right off the bat—the maritime industry's always got some sea changes brewing, but this latest one’s a real head-turner. MacGregor, those wizards of heavy machinery, have sealed a deal to retrofit 35 ships for Wallenius Wilhelmsen. We’re talking a serious overhaul here, folks, with programmable...
Continue Reading
Springbrook's AI Push: Transforming Local Governance
Revolutionizing Government Tech with AI Springbrook Software is positioning itself as a frontrunner in modernizing government tech, unveiling a suite of AI-driven innovations under its Cirrus ERP platform. During their recent conference, Activate 2026, held in Orlando, the commitment to transforming how local governments operate was clear. With new tools like AI Invoicing...
Continue Reading
Aurora Innovation Faces Supply Chain Hurdles & Legal Scrutiny
Aurora's Rough Road: Production Delays Unveiled You could almost hear the collective groan from investors when Aurora Innovation dropped the bombshell about its truck production delays. You know, after the cheery faces at the Q3 financial results reveal gave way to a rather grim reality check—driverless trucking ain't rolling out quite as planned thanks to those pesky...
Continue Reading
Kansas City Life's Q3: Earnings Dip, but Growth Ahead
Striking a Balance: Kansas City Life's Q3 They say numbers don’t lie, and Kansas City Life Insurance just shared their latest. This quarter, things weren't all smooth sailing, but there's a silver lining. For Q3 2026, net income clocked in at $1.7 million, or $0.18 per share, down from last year’s $2.8 million, or $0.29 per share. Sure, it wasn't all sunshine and...
Continue Reading
Reddit's Stock Plunge Sparks Legal Scrutiny
Reddit's Big Gamble: A Risky Shift Investors, grab your coffee, because Reddit (NYSE: RDDT) just gave us a real eyebrow-raiser, and no one's got a clue how deep this rabbit hole goes. They pulled the curtains back and went for a logged-in-only format, and the stock took a nosedive—a good 28% drop, just like that. If you've got a vested interest here, this is your cue to...
Continue Reading
Tampa General Elevates Lokenauth to CFO Amid Growth
Charting New Waters at Tampa General Out here in the blue, the tides of healthcare can swell mighty quick. That's where Tampa General Hospital keeps its anchor firm, announcing Lijah Lokenauth's leap to Executive VP and CFO. If you ask me, it's all about keeping the ship steady—this fella's been steering their financial boat through some hefty waves since 2018....
Continue ReadingTop 5 Most Recently Viewed Articles
Understanding Apollo Commercial Real Estate's Dividend Changes
Apollo Commercial Real Estate Finance's Recent Dividend Change Apollo Commercial Real Estate Finance, Inc. (NYSE: ARI) has made headlines recently because of a significant shift in its dividend policy. The company has announced a 29% cut in its dividend payout, raising concerns and questions among investors about the reasons behind this move and what it means for the...
Continue Reading
DaVinci Roofscapes Announces 2024 Project Award Winners
DaVinci Roofscapes Reveals Award-Winning Projects for 2024 LENEXA, Kan. – DaVinci Roofscapes has proudly announced the winners of the esteemed 2024 Masterpiece Contractor Project of the Year Awards. This annual recognition celebrates outstanding contributions from contractors in the roofing industry across residential and commercial segments. Five remarkable residential...
Continue Reading
Indaptus Therapeutics Expands Clinical Trials for Decoy20
Indaptus Therapeutics Reports Exciting Progress in Clinical Trials Indaptus Therapeutics, Inc. (Nasdaq: INDP), a leader in clinical-stage biotechnology, is making significant advancements in developing innovative treatments for cancer and viral infections. Their latest updates highlight important progress in the Decoy20 clinical program, which focuses on increasing...
Continue Reading
New Oriental Plans Shareholders Meeting for Future Engagements
New Oriental Sets Stage for Annual General Meeting New Oriental Education & Technology Group Inc. (NYSE: EDU) recently announced that it is preparing for its annual general meeting of shareholders. This event is a great opportunity for shareholders to engage with the company's management team and discuss future directions for the organization. Meeting Details and...
Continue Reading
Understanding the Retirement Struggles of Generation X
Generation X, those born between 1965 and 1980, stands on the edge of retirement with a shaky footing. Unlike baby boomers who enjoyed workplace pensions, Gen X had to deal with the decline of such safety nets as they entered their careers. Instead, they’ve mostly relied on 401(k) plans—a shift that hasn’t exactly panned out well for many. The Grim Financial...
Continue Reading